Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review

BackgroundImmune checkpoint inhibitor-associated myocarditis (ICI-M) is a rare yet potentially fatal complication of immunotherapy, with no standardized treatment protocol due to limited data. The use of varying steroid doses has resulted in inconsistent outcomes.MethodsWe retrospectively identified...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiuyue Man, Hong Wang, Chen Chen, Xiaofeng Cong, Lemeng Sun, Xueru Sun, Jing Zhang, Lei Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1455347/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823857024896598016
author Xiuyue Man
Hong Wang
Chen Chen
Xiaofeng Cong
Lemeng Sun
Xueru Sun
Chen Chen
Jing Zhang
Lei Yang
author_facet Xiuyue Man
Hong Wang
Chen Chen
Xiaofeng Cong
Lemeng Sun
Xueru Sun
Chen Chen
Jing Zhang
Lei Yang
author_sort Xiuyue Man
collection DOAJ
description BackgroundImmune checkpoint inhibitor-associated myocarditis (ICI-M) is a rare yet potentially fatal complication of immunotherapy, with no standardized treatment protocol due to limited data. The use of varying steroid doses has resulted in inconsistent outcomes.MethodsWe retrospectively identified patients diagnosed with ICI-M at our institution between January 2020 and February 2024. Additionally, we conducted a comprehensive literature review using PubMed, Embase, and the Cochrane Library to facilitate a comparative analysis of clinical responses. The primary aim was to compare clinical outcomes and therapeutic responses between patients treated with high-dose versus low-dose methylprednisolone.ResultsPatients receiving an initial high-dose intravenous methylprednisolone (1 g/day) exhibited a more rapid reduction in myocardial injury markers, including troponin I/T (cTnI/T), creatine kinase (CK), and N-terminal pro b-type natriuretic peptide (NT-proBNP), compared to those receiving lower doses. This group also demonstrated lower incidences of biomarker rebound and maintained lower levels over time. Additionally, the clinical treatment process was more straightforward in the high-dose group, with treatment efficacy surpassing that observed in patients who received an initial methylprednisolone (mPSL) dose of less than 1 g/day. Regarding prognosis, the incidence of major adverse cardiovascular events (MACE) and cardiovascular mortality was significantly lower in the high-dose group compared to the low-dose group.ConclusionsIn patients with immune checkpoint inhibitor-associated myocarditis, the prompt administration of high-dose corticosteroid pulse therapy (1 g/day) is strongly associated with improved clinical outcomes. This intervention rapidly lowers myocardial injury biomarkers (cTnI/T, CK, NT-proBNP) while minimizing the risk of biomarker rebound, thus optimizing clinical management. Notably, it significantly reduces the incidence of major adverse cardiovascular events (MACE), thereby enhancing patient prognosis. The duration of therapy should be tailored based on clinical response. In cases of steroid resistance, combination therapies may provide additional benefit.
format Article
id doaj-art-e9d5c77c7b5349cfa113eba3227d2201
institution Kabale University
issn 1664-3224
language English
publishDate 2025-02-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-e9d5c77c7b5349cfa113eba3227d22012025-02-12T05:15:02ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.14553471455347Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic reviewXiuyue ManHong WangChen ChenXiaofeng CongLemeng SunXueru SunChen ChenJing ZhangLei YangBackgroundImmune checkpoint inhibitor-associated myocarditis (ICI-M) is a rare yet potentially fatal complication of immunotherapy, with no standardized treatment protocol due to limited data. The use of varying steroid doses has resulted in inconsistent outcomes.MethodsWe retrospectively identified patients diagnosed with ICI-M at our institution between January 2020 and February 2024. Additionally, we conducted a comprehensive literature review using PubMed, Embase, and the Cochrane Library to facilitate a comparative analysis of clinical responses. The primary aim was to compare clinical outcomes and therapeutic responses between patients treated with high-dose versus low-dose methylprednisolone.ResultsPatients receiving an initial high-dose intravenous methylprednisolone (1 g/day) exhibited a more rapid reduction in myocardial injury markers, including troponin I/T (cTnI/T), creatine kinase (CK), and N-terminal pro b-type natriuretic peptide (NT-proBNP), compared to those receiving lower doses. This group also demonstrated lower incidences of biomarker rebound and maintained lower levels over time. Additionally, the clinical treatment process was more straightforward in the high-dose group, with treatment efficacy surpassing that observed in patients who received an initial methylprednisolone (mPSL) dose of less than 1 g/day. Regarding prognosis, the incidence of major adverse cardiovascular events (MACE) and cardiovascular mortality was significantly lower in the high-dose group compared to the low-dose group.ConclusionsIn patients with immune checkpoint inhibitor-associated myocarditis, the prompt administration of high-dose corticosteroid pulse therapy (1 g/day) is strongly associated with improved clinical outcomes. This intervention rapidly lowers myocardial injury biomarkers (cTnI/T, CK, NT-proBNP) while minimizing the risk of biomarker rebound, thus optimizing clinical management. Notably, it significantly reduces the incidence of major adverse cardiovascular events (MACE), thereby enhancing patient prognosis. The duration of therapy should be tailored based on clinical response. In cases of steroid resistance, combination therapies may provide additional benefit.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1455347/fullimmune checkpoint inhibitor-associated myocarditisICI-Mcorticosteroidssteroidstreatment
spellingShingle Xiuyue Man
Hong Wang
Chen Chen
Xiaofeng Cong
Lemeng Sun
Xueru Sun
Chen Chen
Jing Zhang
Lei Yang
Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review
Frontiers in Immunology
immune checkpoint inhibitor-associated myocarditis
ICI-M
corticosteroids
steroids
treatment
title Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review
title_full Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review
title_fullStr Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review
title_full_unstemmed Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review
title_short Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review
title_sort efficacy of high dose steroids versus low dose steroids in the treatment of immune checkpoint inhibitor associated myocarditis a case series and systematic review
topic immune checkpoint inhibitor-associated myocarditis
ICI-M
corticosteroids
steroids
treatment
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1455347/full
work_keys_str_mv AT xiuyueman efficacyofhighdosesteroidsversuslowdosesteroidsinthetreatmentofimmunecheckpointinhibitorassociatedmyocarditisacaseseriesandsystematicreview
AT hongwang efficacyofhighdosesteroidsversuslowdosesteroidsinthetreatmentofimmunecheckpointinhibitorassociatedmyocarditisacaseseriesandsystematicreview
AT chenchen efficacyofhighdosesteroidsversuslowdosesteroidsinthetreatmentofimmunecheckpointinhibitorassociatedmyocarditisacaseseriesandsystematicreview
AT xiaofengcong efficacyofhighdosesteroidsversuslowdosesteroidsinthetreatmentofimmunecheckpointinhibitorassociatedmyocarditisacaseseriesandsystematicreview
AT lemengsun efficacyofhighdosesteroidsversuslowdosesteroidsinthetreatmentofimmunecheckpointinhibitorassociatedmyocarditisacaseseriesandsystematicreview
AT xuerusun efficacyofhighdosesteroidsversuslowdosesteroidsinthetreatmentofimmunecheckpointinhibitorassociatedmyocarditisacaseseriesandsystematicreview
AT chenchen efficacyofhighdosesteroidsversuslowdosesteroidsinthetreatmentofimmunecheckpointinhibitorassociatedmyocarditisacaseseriesandsystematicreview
AT jingzhang efficacyofhighdosesteroidsversuslowdosesteroidsinthetreatmentofimmunecheckpointinhibitorassociatedmyocarditisacaseseriesandsystematicreview
AT leiyang efficacyofhighdosesteroidsversuslowdosesteroidsinthetreatmentofimmunecheckpointinhibitorassociatedmyocarditisacaseseriesandsystematicreview